DOJ Puts C-Suite Execs in Crosshairs
DOJ: “While pursuit of criminal and civil remedies against corporations is important, we should always focus on the individuals responsible for misconduct."
Botox Maker Allergan Sold to AbbVie for $63B
AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.
J&J Gets Boost From Strong Cancer Drug Sales
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
Ex-Salix CFO Fined $1M for Misstating Inventory
The SEC says Adam Derbyshire failed to disclose high wholesaler inventory levels of Salix's drugs resulting from its practice of overselling demand.
Pfizer Beats Estimates on Strength in Key Drugs
Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.
Roche Takes Full Control of Genomic Profiler
The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
Shire Accepts Improved $62B Bid From Takeda
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
Generic Competition Hits Pfizer’s Q2 Sales
The drug maker cites headwinds from losses of market exclusivity for the 14% drop in Essential Health revenues.
J&J Posts $17.7B in Revenue, Misses Estimates
Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
Cardinal Health Buys Medtronic Units for $6B
The deal will expand Cardinal's medical products business but its shares dropped 11.5% on updated guidance for fiscal 2017.
J&J Boosts Drug Roster With $30B Actelion Deal
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.